Streamlined.financeStreamlined.finance
MarketsFind Stocks

Entero Therapeutics, Inc.

NASDAQ

Market Cap.

3.1M

Avg. Volume

454.09K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Entero Therapeutics, Inc.

Entero Therapeutics, Inc. News

Entero Therapeutics, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
firstwavebio.com

About Entero Therapeutics, Inc.

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Entero Therapeutics, Inc. Earnings & Revenue

Entero Therapeutics, Inc. Financials

Table Compare

Compare ENTO metrics with:

   

Earnings & Growth

ENTO

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ENTO

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ENTO

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ENTO

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Entero Therapeutics, Inc. Income

Entero Therapeutics, Inc. Balance Sheet

Entero Therapeutics, Inc. Cash Flow

Entero Therapeutics, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Entero Therapeutics, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Entero Therapeutics, Inc. Executives

NameRole
Mr. James R. Sapirstein M.B.A., R.Ph.Chief Executive Officer & Chairman
Ms. Sarah Romano CPAChief Financial Officer
Ms. Amy Chandler-SkerkisVice President of Regulatory Affairs, QA & Compliance
Ms. Jennifer A. Sealey-Voyksner Ph.D.Senior Vice President for Research & Development
Mr. Martin Krusin M.B.A.Senior Vice President of Corporate Development
NameRoleGenderDate of BirthPay
Mr. James R. Sapirstein M.B.A., R.Ph.Chief Executive Officer & ChairmanMale1961906.2K
Ms. Sarah Romano CPAChief Financial OfficerFemale1980624.88K
Ms. Amy Chandler-SkerkisVice President of Regulatory Affairs, QA & ComplianceFemale1968

--

Ms. Jennifer A. Sealey-Voyksner Ph.D.Senior Vice President for Research & DevelopmentFemale

--

Mr. Martin Krusin M.B.A.Senior Vice President of Corporate DevelopmentMale

--

Entero Therapeutics, Inc. Insider Trades

Date9 Oct
NameRomano Sarah
RoleChief Financial Officer
TransactionDisposed
TypeS-Sale
Shares476
Date9 Aug
NameRamdeen Timothy R.
RoleDirector
TransactionDisposed
Type
Shares0
Date2 Jul
NameRomano Sarah
RoleChief Financial Officer
TransactionDisposed
TypeS-Sale
Shares621
Date2 Jul
NameSAPIRSTEIN JAMES
RoleChairman and CEO
TransactionDisposed
TypeS-Sale
Shares1289
Date11 Jun
NameKHOSLA CHAITAN PHD
RoleDirector
TransactionAcquired
TypeA-Award
Shares24889
DateNameRoleTransactionTypeShares
9 OctRomano SarahChief Financial OfficerDisposedS-Sale476
9 AugRamdeen Timothy R.DirectorDisposed0
2 JulRomano SarahChief Financial OfficerDisposedS-Sale621
2 JulSAPIRSTEIN JAMESChairman and CEODisposedS-Sale1289
11 JunKHOSLA CHAITAN PHDDirectorAcquiredA-Award24889

Discover More

Streamlined Academy

Entero Therapeutics, Inc.

NASDAQ

Market Cap.

3.1M

Avg. Volume

454.09K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Entero Therapeutics, Inc. News

Entero Therapeutics, Inc. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Entero Therapeutics, Inc. Earnings & Revenue

Entero Therapeutics, Inc. Income

Entero Therapeutics, Inc. Balance Sheet

Entero Therapeutics, Inc. Cash Flow

Entero Therapeutics, Inc. Financials Over Time

Entero Therapeutics, Inc. Executives

NameRole
Mr. James R. Sapirstein M.B.A., R.Ph.Chief Executive Officer & Chairman
Ms. Sarah Romano CPAChief Financial Officer
Ms. Amy Chandler-SkerkisVice President of Regulatory Affairs, QA & Compliance
Ms. Jennifer A. Sealey-Voyksner Ph.D.Senior Vice President for Research & Development
Mr. Martin Krusin M.B.A.Senior Vice President of Corporate Development
NameRoleGenderDate of BirthPay
Mr. James R. Sapirstein M.B.A., R.Ph.Chief Executive Officer & ChairmanMale1961906.2K
Ms. Sarah Romano CPAChief Financial OfficerFemale1980624.88K
Ms. Amy Chandler-SkerkisVice President of Regulatory Affairs, QA & ComplianceFemale1968

--

Ms. Jennifer A. Sealey-Voyksner Ph.D.Senior Vice President for Research & DevelopmentFemale

--

Mr. Martin Krusin M.B.A.Senior Vice President of Corporate DevelopmentMale

--

Entero Therapeutics, Inc. Insider Trades

Date9 Oct
NameRomano Sarah
RoleChief Financial Officer
TransactionDisposed
TypeS-Sale
Shares476
Date9 Aug
NameRamdeen Timothy R.
RoleDirector
TransactionDisposed
Type
Shares0
Date2 Jul
NameRomano Sarah
RoleChief Financial Officer
TransactionDisposed
TypeS-Sale
Shares621
Date2 Jul
NameSAPIRSTEIN JAMES
RoleChairman and CEO
TransactionDisposed
TypeS-Sale
Shares1289
Date11 Jun
NameKHOSLA CHAITAN PHD
RoleDirector
TransactionAcquired
TypeA-Award
Shares24889
DateNameRoleTransactionTypeShares
9 OctRomano SarahChief Financial OfficerDisposedS-Sale476
9 AugRamdeen Timothy R.DirectorDisposed0
2 JulRomano SarahChief Financial OfficerDisposedS-Sale621
2 JulSAPIRSTEIN JAMESChairman and CEODisposedS-Sale1289
11 JunKHOSLA CHAITAN PHDDirectorAcquiredA-Award24889

Streamlined Academy

Website screenshot
HealthcareBiotechnology
firstwavebio.com

About Entero Therapeutics, Inc.

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Entero Therapeutics, Inc.

Entero Therapeutics, Inc. Financials

Table Compare

Compare ENTO metrics with:

   

Earnings & Growth

ENTO

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

ENTO

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

ENTO

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

ENTO

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Entero Therapeutics, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioStrong Sell
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)